Tag:

Parkinson's disease

Latest Headlines

Latest Headlines

Civitas, NeuroDerm, EyeGate to pursue IPO dreams, combined $165M on the line

Israel's NeuroDerm filed for a stock offering on the basis of its subcutaneous formulation for treating Parkinson's; Civitas, the developer of an inhaled formulation for the disease, is expected to debut on the Nasdaq Sept. 24; and EyeGate Pharmaceuticals, which employs low-voltage electrical current to deliver eye medication, also just filed for an IPO.

Parkinson's biotech NeuroDerm joins the IPO queue with a $65M pitch

Israel's NeuroDerm is developing a wearable treatment solution for patients with Parkinson's disease, and the biotech is plotting a $65 million IPO to get its lead candidates across the finish line.

Parkinson's diagnostics expand as FDA clears wearable, researchers unveil smartphone app

Researchers are applying the full range of mobile technology to Parkinson's disease diagnostics. This week a pair of new technologies came to the fore, with a wearable device is cleared by FDA and a smartphone app unveiled at the British Science Festival.

Study finds blood-brain barrier opening can be controlled, enabling enhanced drug delivery

Columbia University scientists showed that it is possible to control the size of the blood-brain barrier opening by varying the pressure of an ultrasound beam, a discovery that could herald major breakthroughs in the treatment of neurological diseases.

Intel, Michael J. Fox Foundation start smartwatch study to track Parkinson's patients

A couple of major players are making moves to get wearable med tech a bit closer to reality. Intel has partnered with the Michael J. Fox Foundation to collect data via smartwatches on Parkinson's disease patients, tracking the progression of disease.

Anti-inflammatory drug stops Parkinson's neuron loss in rats

An experimental anti-inflammatory drug delivered via a shot in the skin prevents neuron loss in rats with Parkinson's disease, according to a new study by researchers from Emory University School of Medicine in Atlanta.

Phase II trial kicks off for sublingually delivered Parkinson's therapy

A sublingually delivered thin film strip to treat advanced Parkinson's disease kicked off its Phase II clinical trial following discussions with the FDA, Cynapsus Therapeutics announced July 16.

Chemical switch could be drug target for neurodegenerative disease

A chemical switch that controls the transformation of neural stem cells into neurons and keeps existing nerve cells in the brain alive may be a viable target for neurodegenerative disorders such as Alzheimer's, Parkinson's and autism.

Protein found in naked mole rats could shed light on Alzheimer's, Parkinson's development

A new study identifying a protein associated with the remarkable longevity of the naked mole rat may provide clues for preventing aging-related diseases in humans, like Alzheimer's and Parkinson's.

High protein levels linked to cell death in Parkinson's

Researchers may have discovered how a genetic mechanism in a common cause of Parkinson's works to destroy brain cells in patients--a finding that could help scientists develop new therapies for the devastating disease.